Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINIMISE: MMF in limited cutaneous systemic sclerosis
NCT04927390Phase 2Unknown
- Sponsor
- University College London
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mycophenolate mofetil in limited cutaneous systemic sclerosis (lcSSc) (2 arms), sponsored by University College London. Primary endpoints: Total number of patients screened at 12 months, Proportion of participants who provide consent at 12 months and 8 more. Status: unknown.
02
Drugs
mycophenolate mofetil
03
Conditions
limited cutaneous systemic sclerosis (lcSSc)
Beyond the preview
Go deeper on NCT04927390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927390.